Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Active not recruiting 5Recruiting 4Completed 4Terminated 2Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 36Gastrointestinal 18CNS 7Thoracic 6Breast 6Endocrine 5Tumor-Agnostic 4Head & Neck 4Gynecologic 4Sarcoma 3Dermatologic 3Plasma cell 2Other solid neoplasm 2NET 2Other hematologic neoplasm 1

Conditions

Thyroid Neoplasms 1Thyroid Diseases 1Thyroid Carcinoma, Anaplastic 1Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Neoplasms 1Melanoma 1Head and Neck Squamous Cell Cancer 1Central Nervous System Neoplasms 1Carcinoma, Medullary 1Adenocarcinoma 1

Interventions

Cisplatin 263Radiotherapy 166Cetuximab 159Docetaxel 105Fluorouracil 104pembrolizumab 94Radiotherapy, Intensity-Modulated 83Carboplatin 80Paclitaxel 73Nivolumab 59Erlotinib Hydrochloride 35Surveys and Questionnaires 32Gemcitabine 32durvalumab 30Radiation 29Drug Therapy 25Immunohistochemistry 21Gefitinib 21Capecitabine 21tremelimumab 18Bevacizumab 18Surgical Procedures, Operative 17Sorafenib 17Magnetic Resonance Spectroscopy 17Ipilimumab 17Pemetrexed 16lenvatinib 15atezolizumab 15Radiosurgery 15Gene Expression Profiling 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × cabozantinib × Head & Neck × Clear all
NCT05660954 2026-05-04

CABOTHYROID

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
41 enrolled
Head & Neck

Neoplasms, Thyroid Diseases

NCT04400474 2025-06-19

CABATEN

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
93 enrolled 17 charts
CNSEndocrineHead & NeckNET

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

NCT03667482 2024-07-23

Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
20 enrolled
Head & Neck

Head and Neck Squamous Cell Cancer

NCT01709435 2023-12-22

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
41 enrolled 20 charts
CNSDermatologicHead & Neck

Melanoma, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡